Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$7.59 -2.3%	$8.11	$6.85 ▼ $28.11	$444.97M	-0.07	588,378 shs	620,298 shs
CGEN Compugen	$1.26 -2.3%	$1.46	$1.13 ▼ $2.66	$115.12M	2.61	390,039 shs	114,992 shs
UPB Upstream Bio	$8.73 -1.2%	$8.03	$5.14 ▼ $29.46	$468.71M	N/A	328,210 shs	324,835 shs
VERV Verve Therapeutics	$4.23 -5.6%	$4.99	$2.86 ▼ $9.31	$377.08M	1.82	1.82 million shs	2.11 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	-2.53%	-13.65%	-2.57%	-25.66%	-72.62%
CGEN Compugen	-2.33%	-14.86%	-1.56%	-50.97%	-40.85%
UPB Upstream Bio	-1.13%	+1.04%	+33.69%	+10.23%	+872,999,900.00%
VERV Verve Therapeutics	-5.58%	-18.50%	+24.05%	-48.16%	-30.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEM Cullinan Therapeutics	2.5323 of 5 stars	3.5	2.0	0.0	0.0	2.9	2.5	0.6
CGEN Compugen	1.8792 of 5 stars	3.5	4.0	0.0	0.0	2.2	0.0	0.0
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	3.5247 of 5 stars	4.5	2.0	0.0	0.0	2.8	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEM Cullinan Therapeutics	3.00	Buy	$33.50	341.37% Upside
CGEN Compugen	3.00	Buy	$4.00	217.46% Upside
UPB Upstream Bio	3.00	Buy	$56.50	547.19% Upside
VERV Verve Therapeutics	3.00	Buy	$25.75	508.75% Upside

Current Analyst Ratings Breakdown

Latest CGEN, CGEM, UPB, and VERV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2025	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
4/15/2025	VERV Verve Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $24.00
4/15/2025	VERV Verve Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
4/15/2025	VERV Verve Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$32.00 ➝ $39.00
4/14/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $25.00
3/25/2025	VERV Verve Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/25/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/7/2025	CGEM Cullinan Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$38.00 ➝ $35.00
3/4/2025	VERV Verve Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $15.00
2/28/2025	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
2/28/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $15.00

(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$10.61 per share	N/A
CGEN Compugen	$27.86M	4.04	N/A	N/A	$0.73 per share	1.73
UPB Upstream Bio	$2.37M	197.77	N/A	N/A	N/A	∞
VERV Verve Therapeutics	$32.33M	11.66	N/A	N/A	$7.31 per share	0.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEM Cullinan Therapeutics	-$153.16M	-$2.91	N/A	N/A	N/A	N/A	-26.54%	-25.32%	5/13/2025 (Estimated)
CGEN Compugen	-$18.75M	-$0.16	63.00	N/A	N/A	2.67%	2.62%	1.36%	5/19/2025 (Estimated)
UPB Upstream Bio	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	6/11/2025 (Estimated)
VERV Verve Therapeutics	-$200.07M	-$2.35	N/A	N/A	N/A	-807.65%	-35.23%	-27.65%	5/14/2025 (Estimated)

Latest CGEN, CGEM, UPB, and VERV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	CGEM Cullinan Therapeutics	-$0.80	N/A	N/A	N/A	N/A	N/A
5/19/2025	Q1 2025	CGEN Compugen	-$0.06	N/A	N/A	N/A	$3.70 million	N/A
5/14/2025	Q1 2025	VERV Verve Therapeutics	-$0.71	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	CGEM Cullinan Therapeutics	-$0.78	-$0.74	+$0.04	-$0.74	N/A	N/A
5/6/2025	Q1 2025	UPB Upstream Bio	-$0.49	-$0.51	-$0.02	-$0.51	$0.71 million	$0.57 million
3/4/2025	Q4 2024	CGEN Compugen	$0.07	-$0.07	-$0.14	-$0.07	$17.47 million	$1.47 million
2/27/2025	Q4 2024	CGEM Cullinan Therapeutics	-$0.75	-$0.73	+$0.02	-$0.73	N/A	N/A
2/27/2025	Q4 2024	VERV Verve Therapeutics	-$0.72	-$0.58	+$0.14	-$0.58	$3.94 million	$13.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEM Cullinan Therapeutics	N/A	24.46	24.46
CGEN Compugen	N/A	4.14	4.14
UPB Upstream Bio	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	13.05	13.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEM Cullinan Therapeutics	86.31%
CGEN Compugen	12.22%
UPB Upstream Bio	N/A
VERV Verve Therapeutics	97.11%

Insider Ownership

Company	Insider Ownership
CGEM Cullinan Therapeutics	7.16%
CGEN Compugen	9.50%
UPB Upstream Bio	N/A
VERV Verve Therapeutics	19.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEM Cullinan Therapeutics	30	59.02 million	54.69 million	Optionable
CGEN Compugen	70	89.24 million	80.76 million	Optionable
UPB Upstream Bio	38	53.69 million	N/A	N/A
VERV Verve Therapeutics	110	89.14 million	68.32 million	Optionable

CGEN, CGEM, UPB, and VERV Headlines

Recent News About These Companies

LEQVIO Strengthens Position as Leader in Cholesterol-Lowering Therapies Across Seven Major Markets | DelveInsight

May 10 at 10:48 AM | prnewswire.co.uk

Verve Therapeutics (VERV) Expected to Announce Quarterly Earnings on Wednesday

May 9 at 7:31 AM | marketbeat.com

Verve Therapeutics Stock Short Interest Report | NASDAQ:VERV | Benzinga

May 8 at 2:40 AM | benzinga.com

Verve Therapeutics’ SWOT analysis: gene-editing stock shows promise amid challenges

May 7 at 9:40 PM | investing.com

Biotech Stocks Fall After FDA Names Vinay Prasad To Succeed Marks at CBER

May 7 at 5:11 AM | biospace.com

Verve Therapeutics, Inc. (NASDAQ:VERV) Stock Position Lifted by BVF Inc. IL

May 6, 2025 | marketbeat.com

April 2025 Recap: Drug Pipeline Updates

May 5, 2025 | empr.com

PDT Partners LLC Sells 128,512 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

May 5, 2025 | marketbeat.com

‘Safer’ CRISPR: Base Editing Breaks Through in the Clinic as Beam, Verve Advance

May 5, 2025 | biospace.com

Susquehanna Fundamental Investments LLC Invests $1.64 Million in Verve Therapeutics, Inc. (NASDAQ:VERV)

May 3, 2025 | marketbeat.com

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 2, 2025 | globenewswire.com

Schonfeld Strategic Advisors LLC Boosts Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)

May 2, 2025 | marketbeat.com

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Sold by T. Rowe Price Investment Management Inc.

April 30, 2025 | marketbeat.com

1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street

April 29, 2025 | fool.com

One-Time Gene Editing Therapy Shows Big Promise for Cholesterol

April 29, 2025 | medindia.net

Syon Capital LLC Takes $302,000 Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

April 28, 2025 | marketbeat.com

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Sold by Renaissance Technologies LLC

April 28, 2025 | marketbeat.com

Verve Therapeutics, Inc. (NASDAQ:VERV) Position Reduced by JPMorgan Chase & Co.

April 26, 2025 | marketbeat.com

Verve Therapeutics, Inc. (NASDAQ:VERV) Given Average Recommendation of "Buy" by Analysts

April 21, 2025 | marketbeat.com

Why Verve Therapeutics Zoomed 40% Higher This Week

April 18, 2025 | fool.com

Verve Therapeutics Sees Unusually Large Options Volume (NASDAQ:VERV)

April 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
By Chris Markoch | April 16, 2025
View Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
Texas Instruments: Earnings Beat, Upbeat Guidance Fuel Recovery
By Jeffrey Neal Johnson | April 27, 2025
View Texas Instruments: Earnings Beat, Upbeat Guidance Fuel Recovery
Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast
By Jeffrey Neal Johnson | May 9, 2025
View Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast

CGEN, CGEM, UPB, and VERV Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

$7.59 -0.18 (-2.32%)

As of 05/9/2025 03:58 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Compugen NASDAQ:CGEN

$1.26 -0.03 (-2.33%)

As of 05/9/2025 04:00 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Upstream Bio NASDAQ:UPB

$8.73 -0.11 (-1.24%)

As of 05/9/2025 03:51 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Verve Therapeutics NASDAQ:VERV

$4.23 -0.25 (-5.58%)

As of 05/9/2025 04:00 PM Eastern

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time